Plasma Somatostatin in Advanced Heart Failure: Association with Cardiac Filling Pressures and Outcome

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Plasma Somatostatin in Advanced Heart Failure : Association with Cardiac Filling Pressures and Outcome. / Deis, Tania; Balling, Louise; Rossing, Kasper; Boesgaard, Søren; Kistorp, Caroline Michaela; Wolsk, Emil; Gøtze, Jens Peter; Rehfeld, Jens Federik; Gustafsson, Finn.

I: Cardiology, Bind 145, Nr. 12, 2020, s. 769–778.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Deis, T, Balling, L, Rossing, K, Boesgaard, S, Kistorp, CM, Wolsk, E, Gøtze, JP, Rehfeld, JF & Gustafsson, F 2020, 'Plasma Somatostatin in Advanced Heart Failure: Association with Cardiac Filling Pressures and Outcome', Cardiology, bind 145, nr. 12, s. 769–778. https://doi.org/10.1159/000510284

APA

Deis, T., Balling, L., Rossing, K., Boesgaard, S., Kistorp, C. M., Wolsk, E., Gøtze, J. P., Rehfeld, J. F., & Gustafsson, F. (2020). Plasma Somatostatin in Advanced Heart Failure: Association with Cardiac Filling Pressures and Outcome. Cardiology, 145(12), 769–778. https://doi.org/10.1159/000510284

Vancouver

Deis T, Balling L, Rossing K, Boesgaard S, Kistorp CM, Wolsk E o.a. Plasma Somatostatin in Advanced Heart Failure: Association with Cardiac Filling Pressures and Outcome. Cardiology. 2020;145(12):769–778. https://doi.org/10.1159/000510284

Author

Deis, Tania ; Balling, Louise ; Rossing, Kasper ; Boesgaard, Søren ; Kistorp, Caroline Michaela ; Wolsk, Emil ; Gøtze, Jens Peter ; Rehfeld, Jens Federik ; Gustafsson, Finn. / Plasma Somatostatin in Advanced Heart Failure : Association with Cardiac Filling Pressures and Outcome. I: Cardiology. 2020 ; Bind 145, Nr. 12. s. 769–778.

Bibtex

@article{ef07cc0042934bcf9128a7085745e651,
title = "Plasma Somatostatin in Advanced Heart Failure: Association with Cardiac Filling Pressures and Outcome",
abstract = "Background: Somatostatin inhibits intestinal motility and hormonal secretion and is a potent arterial vasoconstrictor of the splanchnic blood flow. It is unknown if somatostatin concentrations are associated with central hemodynamic measurements in patients with advanced heart failure (HF). Methods: A prospective study of HF patients with a left ventricular ejection fraction (LVEF) 45% referred to right heart catheterization (RHC) for evaluation for heart transplantation (HTX) or left ventricular assist device (LVAD). Results: Fifty-Three patients were included with mean LVEF 18 ± 8% and majority in NYHA-class III-IV (79%). Median plasma somatostatin concentration was 18 pmol/L. In univariable regression analysis, log(somatostatin) was associated with increased central venous pressure (CVP; r2 = 0.14, p = 0.003) and a reduced cardiac index (CI; r2 = 0.15, p = 0.004). When adjusted for selected clinical variables (age, gender, LVEF, eGFR and BMI), log(somatostatin) remained a significant predictor of CVP (p = 0.044). Increased somatostatin concentrations predicted mortality in multivariable models (hazard ratio: 5.2 [1.2-22.2], p = 0.026) but not the combined endpoint of death, LVAD implantation or HTX. Conclusions: Somatostatin concentrations were associated with CVP and CI in patients with HF. The pathophysiological mechanism may be related to congestion and/or hypoperfusion of the intestine. Somatostatin was an independent predictor of mortality in advanced HF. ",
author = "Tania Deis and Louise Balling and Kasper Rossing and S{\o}ren Boesgaard and Kistorp, {Caroline Michaela} and Emil Wolsk and G{\o}tze, {Jens Peter} and Rehfeld, {Jens Federik} and Finn Gustafsson",
year = "2020",
doi = "10.1159/000510284",
language = "English",
volume = "145",
pages = "769–778",
journal = "Cardiology",
issn = "0008-6312",
publisher = "S Karger AG",
number = "12",

}

RIS

TY - JOUR

T1 - Plasma Somatostatin in Advanced Heart Failure

T2 - Association with Cardiac Filling Pressures and Outcome

AU - Deis, Tania

AU - Balling, Louise

AU - Rossing, Kasper

AU - Boesgaard, Søren

AU - Kistorp, Caroline Michaela

AU - Wolsk, Emil

AU - Gøtze, Jens Peter

AU - Rehfeld, Jens Federik

AU - Gustafsson, Finn

PY - 2020

Y1 - 2020

N2 - Background: Somatostatin inhibits intestinal motility and hormonal secretion and is a potent arterial vasoconstrictor of the splanchnic blood flow. It is unknown if somatostatin concentrations are associated with central hemodynamic measurements in patients with advanced heart failure (HF). Methods: A prospective study of HF patients with a left ventricular ejection fraction (LVEF) 45% referred to right heart catheterization (RHC) for evaluation for heart transplantation (HTX) or left ventricular assist device (LVAD). Results: Fifty-Three patients were included with mean LVEF 18 ± 8% and majority in NYHA-class III-IV (79%). Median plasma somatostatin concentration was 18 pmol/L. In univariable regression analysis, log(somatostatin) was associated with increased central venous pressure (CVP; r2 = 0.14, p = 0.003) and a reduced cardiac index (CI; r2 = 0.15, p = 0.004). When adjusted for selected clinical variables (age, gender, LVEF, eGFR and BMI), log(somatostatin) remained a significant predictor of CVP (p = 0.044). Increased somatostatin concentrations predicted mortality in multivariable models (hazard ratio: 5.2 [1.2-22.2], p = 0.026) but not the combined endpoint of death, LVAD implantation or HTX. Conclusions: Somatostatin concentrations were associated with CVP and CI in patients with HF. The pathophysiological mechanism may be related to congestion and/or hypoperfusion of the intestine. Somatostatin was an independent predictor of mortality in advanced HF.

AB - Background: Somatostatin inhibits intestinal motility and hormonal secretion and is a potent arterial vasoconstrictor of the splanchnic blood flow. It is unknown if somatostatin concentrations are associated with central hemodynamic measurements in patients with advanced heart failure (HF). Methods: A prospective study of HF patients with a left ventricular ejection fraction (LVEF) 45% referred to right heart catheterization (RHC) for evaluation for heart transplantation (HTX) or left ventricular assist device (LVAD). Results: Fifty-Three patients were included with mean LVEF 18 ± 8% and majority in NYHA-class III-IV (79%). Median plasma somatostatin concentration was 18 pmol/L. In univariable regression analysis, log(somatostatin) was associated with increased central venous pressure (CVP; r2 = 0.14, p = 0.003) and a reduced cardiac index (CI; r2 = 0.15, p = 0.004). When adjusted for selected clinical variables (age, gender, LVEF, eGFR and BMI), log(somatostatin) remained a significant predictor of CVP (p = 0.044). Increased somatostatin concentrations predicted mortality in multivariable models (hazard ratio: 5.2 [1.2-22.2], p = 0.026) but not the combined endpoint of death, LVAD implantation or HTX. Conclusions: Somatostatin concentrations were associated with CVP and CI in patients with HF. The pathophysiological mechanism may be related to congestion and/or hypoperfusion of the intestine. Somatostatin was an independent predictor of mortality in advanced HF.

U2 - 10.1159/000510284

DO - 10.1159/000510284

M3 - Journal article

C2 - 33027795

AN - SCOPUS:85092786214

VL - 145

SP - 769

EP - 778

JO - Cardiology

JF - Cardiology

SN - 0008-6312

IS - 12

ER -

ID: 251642725